Search

Methotrexate, skin ulcer, extranodal NK/T-cell lymphoma, , Epstein-Barr virus Keywords: extranodal NK/T-cell lymphoma; ; methotrexate; Epstein-Barr virus; skin ulcer EN extranodal NK/T-cell lymphoma methotrexate Epstein-Barr virus skin ulcer 849 852 4 11/11/22 20221201 NES 221201 I Sir, i Immunosuppressive therapies such as methotrexate (MTX) can cause oligoclonal or monoclonal lymphoproliferative disorder, which is categorized as other iatrogenic immunodeficiency-associated lymphoproliferative disorders (LPD) in the current WHO classification.1 Most MTX-associated LPDs, including skin lesions, are of B-cell lineage, and only four cases of primary cutaneous MTX-associated T-cell LPD have been reported.2,3 The histologic subtypes of these four cases were angioimmunoblastic T-cell lymphoma, primary cutaneous anaplastic large cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, and MTX-associated T-cell LPD (not further specified), all of which regressed after MTX was discontinued. 4 Yu WW, Hsieh PP, Chuang SS. Cutaneous EBV-positive T-cell lymphoma vs. extranodal NK/T-cell lymphoma: a case report and literature review. [Extracted from the article]

Background: The oncofetal protein insulin‐like growth factor 2 mRNA binding protein‐3 (IMP3) is expressed in various cancers. In this study, we examined the diagnostic utility of IMP3 immunohistochemistry in the context of intravascular large B‐cell lymphoma (IVL). Methods: We obtained 25 skin biopsy (SB) specimens diagnosed as IVL and nine IVL‐negative SB specimens from 27 IVL patients. Additionally, 27 negative SB specimens from 26 non‐IVL patients were obtained from our pathology archives. We performed IMP3 immunohistochemistry on these 61 SB specimens, considering IMP3 expression in any mononuclear cell as positive. In selected cases, triple immunostaining for IMP3, PAX5, and CD34 was performed to analyze the origin and location of IMP3‐positive cells. Results: IMP3 was expressed in most intravascular lymphoma cells in all the 25 SB specimens diagnosed as IVL. Furthermore, our evaluation revealed the presence of intravascular IMP3‐positive B‐cells in five of the nine negative SB specimens from IVL patients; however, this was not observed in the 27 SB specimens from non‐IVL patients. Conclusion: IMP3 was expressed in most IVL cells, and IMP3 immunohistochemistry could serve as a sensitive diagnostic aid for detecting IVL cells in SB. [ABSTRACT FROM AUTHOR]

Signaling lymphocytic activation molecule family member 8 (SLAMF8) / B-lymphocyte activator macrophage expressed/CD353 is a member of the CD2 family. SLAMF8 suppresses macrophage function but enhances the growth of neoplastic mast cells via SHP-2. In this study, we found that some anaplastic large cell lymphoma (ALCL) samples were immunohistochemically positive for SLAMF8. However, we found no significant differences between SLAMF8-positive and SLAMF8-negative ALCL samples with respect to age, gender, site, or prognosis. We also identified SLAMF8 expression in ALCL cell lines, Karpas299, and SU-DHL-1. SLAMF8 knockdown decreased the activation of SHP-2 and the growth of these cell lines, and increased the apoptosis of these cell lines. In addition, we observed the interaction between SLAMF8 and SHP-2 in these cell lines using the DuoLink in situ kit. Taken together, these results suggest that SLAMF8 may enhance the growth of ALCL via SHP-2 interaction. [ABSTRACT FROM AUTHOR]

Activation-induced cytidine deaminase (AID) plays important roles in the development of diffuse large B-cell lymphoma (DLBCL); however, its prognostic value remains controversial. Here, we evaluated AID expression in 71 DLBCL patients treated with R-CHOP by immunohistochemistry and investigated its prognostic significance. AID expression was detected in 40.8% of DLBCL samples and associated with IRF4 expression. Notably, AID expression correlated with shorter progression-free survival and overall survival for patients with high (3-5) international prognostic index (IPI) score. Moreover, it was a strong predictor of poor overall response to salvage therapy after relapse or disease progression, which may suggest its role in promoting the evolution of tumors into highly refractory disease at relapse. Our findings indicate that AID expression effectively discriminates between IPI-high score patients with different survival outcomes, and suggest that initial disease control would be particularly important for the treatment of IPI-high score patients with AID-positive DLBCL. [ABSTRACT FROM AUTHOR]